Peter Reiss

Summary

Country: USA

Publications

  1. ncbi Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel
    Melanie A Thompson
    AIDS Research Consortium of Atlanta, Atlanta, Georgia, USA
    JAMA 304:321-33. 2010
  2. ncbi Pharmacokinetics, pharmacodynamics and safety of once-daily versus twice-daily dosing with enfuvirtide in HIV-infected subjects
    Melanie Thompson
    AIDS Research Consortium of Atlanta, Atlanta, Georgia 30308, USA
    AIDS 20:397-404. 2006
  3. ncbi Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel
    Scott M Hammer
    Division of Infectious Diseases, Columbia University College of Physicians and Surgeons, 630 W 168th St, New York, NY 10032, USA
    JAMA 300:555-70. 2008
  4. ncbi Seven-year efficacy of a lopinavir/ritonavir-based regimen in antiretroviral-naïve HIV-1-infected patients
    Robert L Murphy
    Northwestern University, Chicago, Illinois, USA
    HIV Clin Trials 9:1-10. 2008
  5. ncbi Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel
    Scott M Hammer
    Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York 10032, USA
    JAMA 296:827-43. 2006
  6. ncbi Short-term safety and pharmacodynamics of amdoxovir in HIV-infected patients
    Melanie A Thompson
    AIDS Research Consortium of Atlanta, Georgia, USA
    AIDS 19:1607-15. 2005
  7. ncbi Are adverse events of nevirapine and efavirenz related to plasma concentrations?
    Bregt S Kappelhoff
    Department of Pharmacy Et Pharmacology, Slotervaart Hospital, Amsterdam, The Netherlands
    Antivir Ther 10:489-98. 2005
  8. ncbi Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel
    Patrick G Yeni
    Department of Infectious Diseases, Hopital Bichat Claude Bernard, X Bichat Medical School, Paris, France
    JAMA 292:251-65. 2004
  9. ncbi Twice-daily Trizivir versus Combivir-abacavir in antiretroviral-experienced adults with human immunodeficiency virus-1 infection: a formulation-switch trial
    Margaret A Fischl
    University of Miami, School of Medicine, Department of Medicine, Florida 33136, USA
    Pharmacotherapy 23:1432-40. 2003
  10. ncbi Impact of an educational program on efficacy and adherence with a twice-daily lamivudine/zidovudine/abacavir regimen in underrepresented HIV-infected patients
    M Keith Rawlings
    Southeast Dallas Health Center, Texas, USA
    J Acquir Immune Defic Syndr 34:174-83. 2003

Research Grants

  1. A Community Collaboration to Increase HIV Serostatus Awareness for At Risk AA MSM
    Melanie Thompson; Fiscal Year: 2007

Collaborators

Detail Information

Publications12

  1. ncbi Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel
    Melanie A Thompson
    AIDS Research Consortium of Atlanta, Atlanta, Georgia, USA
    JAMA 304:321-33. 2010
    ....
  2. ncbi Pharmacokinetics, pharmacodynamics and safety of once-daily versus twice-daily dosing with enfuvirtide in HIV-infected subjects
    Melanie Thompson
    AIDS Research Consortium of Atlanta, Atlanta, Georgia 30308, USA
    AIDS 20:397-404. 2006
    ..To investigate the pharmacokinetics, safety/tolerability and antiviral activity of enfuvirtide administered once-daily (QD) versus twice-daily (BID)...
  3. ncbi Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel
    Scott M Hammer
    Division of Infectious Diseases, Columbia University College of Physicians and Surgeons, 630 W 168th St, New York, NY 10032, USA
    JAMA 300:555-70. 2008
    ....
  4. ncbi Seven-year efficacy of a lopinavir/ritonavir-based regimen in antiretroviral-naïve HIV-1-infected patients
    Robert L Murphy
    Northwestern University, Chicago, Illinois, USA
    HIV Clin Trials 9:1-10. 2008
    ..Evaluate efficacy and tolerability of lopinavir/ritonavir (LPV/r) plus stavudine and lamivudine long term in antiretroviral-naïve patients...
  5. ncbi Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel
    Scott M Hammer
    Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York 10032, USA
    JAMA 296:827-43. 2006
    ..The International AIDS Society-USA panel has updated its recommendations as warranted by new developments in the field...
  6. ncbi Short-term safety and pharmacodynamics of amdoxovir in HIV-infected patients
    Melanie A Thompson
    AIDS Research Consortium of Atlanta, Georgia, USA
    AIDS 19:1607-15. 2005
    ..In ART-experienced patients, the antiviral activity was significant in those with no thymidine-analogue mutations and higher baseline CD4+ cell counts...
  7. ncbi Are adverse events of nevirapine and efavirenz related to plasma concentrations?
    Bregt S Kappelhoff
    Department of Pharmacy Et Pharmacology, Slotervaart Hospital, Amsterdam, The Netherlands
    Antivir Ther 10:489-98. 2005
    ..The relationships between adverse events (AEs) and plasma concentrations of nevirapine (NVP) and efavirenz (EFV) were investigated as part of the large, international, randomized 2NN study...
  8. ncbi Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel
    Patrick G Yeni
    Department of Infectious Diseases, Hopital Bichat Claude Bernard, X Bichat Medical School, Paris, France
    JAMA 292:251-65. 2004
    ..Substantial changes in the field of human immunodeficiency virus (HIV) treatment have occurred in the last 2 years, prompting revision of the guidelines for antiretroviral management of adults with established HIV infection...
  9. ncbi Twice-daily Trizivir versus Combivir-abacavir in antiretroviral-experienced adults with human immunodeficiency virus-1 infection: a formulation-switch trial
    Margaret A Fischl
    University of Miami, School of Medicine, Department of Medicine, Florida 33136, USA
    Pharmacotherapy 23:1432-40. 2003
    ....
  10. ncbi Impact of an educational program on efficacy and adherence with a twice-daily lamivudine/zidovudine/abacavir regimen in underrepresented HIV-infected patients
    M Keith Rawlings
    Southeast Dallas Health Center, Texas, USA
    J Acquir Immune Defic Syndr 34:174-83. 2003
    ..In conclusion, in underrepresented patients, the EI used in this study did not affect the efficacy and adherence results with ABC + COM to any greater degree than did RC...
  11. ncbi Once-daily quadruple-drug therapy with adefovir dipivoxil, Lamivudine, Didanosine, and efavirenz in treatment-naive human immunodeficiency virus type 1-infected patients
    Gail Skowron
    Roger Williams Medical Center, Providence, Rhode Island 02908, USA
    J Infect Dis 186:1028-33. 2002
    ....
  12. ncbi Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel
    Patrick G Yeni
    Hopital Bichat Claude Bernard, Department of Infectious Diseases, 46 rue Henri Huchard, Paris, Cedex 18 France 75877
    JAMA 288:222-35. 2002
    ..These updated recommendations are intended to guide practicing physicians actively involved in human immunodeficiency virus (HIV)- and acquired immunodeficiency syndrome (AIDS)-related care...

Research Grants3

  1. A Community Collaboration to Increase HIV Serostatus Awareness for At Risk AA MSM
    Melanie Thompson; Fiscal Year: 2007
    ....